The safety and efficacy of stem cells for the treatment of severe community-acquired bacterial pneumonia: A randomized clinical trial
Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), Bruno François(Inserm), Miguel Sánchez García(Hospital Clínico San Carlos), Ricard Ferrer(Universitat Autònoma de Barcelona), Tom van der Poll(Amsterdam Neuroscience), Gonzalo Hernández(Complejo Hospitalario Universitario de Toledo), Fernando Martínez‐Sagasti(Hospital Clínico San Carlos), Xavier Wittebole(Cliniques Universitaires Saint-Luc), Kathy-Ann Cadogan(Takeda (United States)), Barbara Zhang(Takeda (United States)), Jesús Caballero(Universitat Autònoma de Barcelona), A. C. Sullivan(Takeda (United States)), Olga de la Rosa, Eleuterio Lombardo
Cited by 11
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Intensive Care Medicine|2017|6.8k
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
|Intensive Care Medicine|2021|5.1k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Critical Care Medicine|2017|3.8k